Free Trial

GSK (GSK) Competitors

GSK logo
GBX 1,423.65 +8.15 (+0.58%)
As of 06:57 AM Eastern

GSK vs. AZN, SOPH, ITH, HCM, GRI, INDV, SLS, ERGO, BMY, and SLN

Should you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Sophos Group plc (SOPH.L) (SOPH), Ithaca Energy (ITH), HUTCHMED (HCM), Grainger (GRI), Indivior (INDV), Standard Life UK Smaller Companies Trust (SLS), Ergomed (ERGO), Bloomsbury Publishing (BMY), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical products" industry.

GSK vs.

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

AstraZeneca pays an annual dividend of GBX 234 per share and has a dividend yield of 2.2%. GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 4.2%. AstraZeneca pays out 64.1% of its earnings in the form of a dividend. GSK pays out 96.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

AstraZeneca presently has a consensus price target of GBX 6,303.50, suggesting a potential downside of 40.00%. GSK has a consensus price target of GBX 1,862.50, suggesting a potential upside of 30.83%. Given GSK's higher possible upside, analysts plainly believe GSK is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
GSK
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca13.01% 17.76% 7.68%
GSK 8.02%18.08%9.56%

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca£66.95B3.02£8.71B£364.8328.80
GSK£31.14B1.86£2.50B£61.9123.00

AstraZeneca has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

In the previous week, GSK had 2 more articles in the media than AstraZeneca. MarketBeat recorded 4 mentions for GSK and 2 mentions for AstraZeneca. GSK's average media sentiment score of 0.61 beat AstraZeneca's score of 0.33 indicating that GSK is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GSK
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

51.0% of AstraZeneca shares are held by institutional investors. Comparatively, 45.3% of GSK shares are held by institutional investors. 0.0% of AstraZeneca shares are held by insiders. Comparatively, 1.6% of GSK shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AstraZeneca received 774 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.78% of users gave AstraZeneca an outperform vote while only 50.37% of users gave GSK an outperform vote.

CompanyUnderperformOutperform
AstraZenecaOutperform Votes
1865
63.78%
Underperform Votes
1059
36.22%
GSKOutperform Votes
1091
50.37%
Underperform Votes
1075
49.63%

Summary

AstraZeneca beats GSK on 10 of the 19 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GSK vs. The Competition

MetricGSKDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£57.77B£94.49B£5.43B£2.68B
Dividend Yield4.25%2.47%5.22%4.96%
P/E Ratio23.0023.6026.79134.50
Price / Sales1.86162.58394.72216,044.87
Price / Cash8.1517.5938.2528.03
Price / Book4.323.026.863.79
Net Income£2.50B£3.43B£3.22B£5.88B
7 Day Performance4.68%1.19%6.83%7.72%
1 Month Performance7.60%1.27%13.73%29.23%
1 Year Performance-18.93%-8.60%18.22%118.50%

GSK Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GSK
GSK
3.6117 of 5 stars
GBX 1,423.65
+0.6%
GBX 1,862.50
+30.8%
-20.3%£57.77B£31.14B23.0070,212High Trading Volume
AZN
AstraZeneca
1.3154 of 5 stars
£102.72
+0.3%
GBX 6,303.50
-38.6%
-13.9%£197.64B£66.95B28.1683,500Gap Down
SOPH
Sophos Group plc (SOPH.L)
N/AN/AN/AN/A£2.99B£726.90M341.41520
ITH
Ithaca Energy
N/AGBX 140
-0.1%
N/A+9.5%£2.92B£3.55B15.99220Trending News
HCM
HUTCHMED
N/AGBX 214
-3.3%
N/A-37.3%£2.32B£771.01M-54.621,760News Coverage
High Trading Volume
GRI
Grainger
2.9758 of 5 stars
GBX 216.50
-0.5%
GBX 317.50
+46.7%
-11.1%£1.60B£276.05M-1,443.33372Earnings Report
Dividend Increase
INDV
Indivior
1.7209 of 5 stars
GBX 845.50
+0.6%
GBX 1,650
+95.2%
-35.9%£1.32B£1.40B-701.041,000
SLS
Standard Life UK Smaller Companies Trust
N/AN/AN/AN/A£715.41M£222.48M3.3710
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
BMY
Bloomsbury Publishing
3.1142 of 5 stars
GBX 627.62
+1.2%
GBX 825
+31.4%
+6.2%£506.45M£382.40M13.4334,300News Coverage
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume

Related Companies and Tools


This page (LON:GSK) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners